Recall Register

Drug recall: JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90)…

Class II FDA enforcement event 91879. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Labeling: Label Mix-up

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Boehringer Ingelheim Pharmaceuticals, Inc. started this drug recall on 9 Mar 2023. The firm address in the FDA record is in Ridgefield, CT. FDA put the recall in Class II. FDA event 91879 has 1 product record. The first FDA enforcement report date is 29 Mar 2023. The record gives the status Terminated, with the termination date 4 Dec 2023.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Product was distributed nationwide within the United States and PR

Recalling firm

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 91879: product records
Recall numberProductQuantityClassStatusReport date
D-0468-2023JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA69,375 bottlesClass IITerminated29 Mar 2023

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2023
281
Share of these events in Class II
59%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
10

Other events of the firm

Official channels

Cite this page

Recall Register. FDA enforcement event 91879. https://recallregister.com/fda/ii/91879/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Product was distributed nationwide within the United States and PR
What quantity of product is in FDA event 91879?
The FDA record gives this quantity: 69,375 bottles
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2023 have the same class?
59% of the 281 drug events that started in 2023 are in Class II.